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Abstract
We wanted to determine whether methamphetamine use affects a subset of plasma proteins in HIV-infected persons.
Plasma samples from two visits were identified for subjects from four groups: HIV+, ongoing, persistent METH use; HIV+,
short-term METH abstinent; HIV+, long term METH abstinence; HIV negative, no history of METH use. Among 390 proteins
identified, 28 showed significant changes in expression in the HIV+/persistent METH+ group over the two visits, which were
not attributable to HIV itself. These proteins were involved in complement, coagulation pathways and oxidative stress.
Continuous METH use is an unstable condition, altering levels of a number of plasma proteins.
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Introduction
Methamphetamine (METH) is an widely abused drug world-
wide [1], not only because of its general harmful effects on organ
function and physiology, but also because its use can lead to the
transmission of HIV and other infectious diseases. This commonly
occurs through needle sharing and risky sexual behaviors [2,3].
The use of METH itself has adverse effects on the central nervous
system (CNS) with a broad range of clinical outcomes [4]. The
acute effects of METH depend on the amount of drug used and
route of administration [5]. With longer term use, METH is
neurotoxic, damaging dopaminergic nerve terminals, most
profoundly in the striatum [6,7]. Long-term dopamine depletion
and microglial activation is implicated in METH-induced
neurotoxicity through reactive oxygen species, increased release
of 5-hydroxytryptamine (5-HT), and loss of function in tryptophan
hydroxylase and the serotonin transporter [7]. METH also has
untoward actions on the immune system, yielding predominantly
inhibitor effects [8,9,10]. Due to its effects on the immune and the
central nervous systems, the multiple effects of METH are further
complicated in the context of HIV-1 infection. When combined,
METH use and HIV infection may have even more devastating
effects [2,11,12,13].
Mechanisms underlying cognitive impairment resulting from
HIV-1 infection and concurrent METH use are far from understood
and diagnosis is currently limited to clinical evaluation and
neurocognitive assessments [14]. During the last decade much
experimental effort has been directed towards discovery of
biomarkers in body fluids to aid in diagnosis and monitoring of
neurocognitive disease, with a special emphasis on blood which is the
easiest clinical sample to obtain. Protein biomarkers are an especially
important target, and blood contains useful and unique proteomic
signatures – proteins and their fragments potentially changed due to
pathologicalchanges.Howeverthereareseveralobstaclesinprogress
of discovery new biomarkers [15] such as linking particular
biomarkers to pathology of disease and weakness of quantitation,
thereforeproper validation techniques of individual proteins is a very
complex procedure [16]. We aimed to obtain clues to the effects of
METH use on the blood plasma proteome. To accomplish this, our
study was designed to capture changes in host responses following
different durations of METH use or abstinence in HIV-infected
individuals. We compared changes between two visits for in four
groups of individuals. The first three groups consisted of HIV-
infected METH users who either continued abusing METH(HIV+/
persistent METH+), subjects who stopped METH and reported a
short period (e.g., less than 12 weeks) of abstinence (HIV+/ST
METH abstinent), or subjects who stopped METH and reported a
longer period (e.g., at least 12 weeks) of abstinence (HIV+/LT
METH abstinent). A fourth group consisted of uninfected controls
who did not meet criteria for a METH use disorder and who
reported no use of METH (HIV2/METH2). Among numerous
methods used in proteomic profiling, we selected an isobaric tag for
relative and absolute quantitation (iTRAQ) shotgun proteomic
approach. This tandem mass spectrometry (MS/MS) profiling
platform enables the quantification of identified peptides which is
further translated to protein quantitation. Such large-scale acquisi-
tion and analysis can generate statistically significant valuable
information with the ability to address existing questions and
formulate new hypotheses, as successfully implemented here.
Profiling of samples from HIV+ individuals who report
abstinence from METH may allow for a better understanding of
the molecular mechanisms underlying reversible (short-term), and
potentially non-reversible (long-term) effects, of METH use within
the context of HIV-1.
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Clinical samples
The University of California San Diego (UCSD) and University
of Nebraska Medical Center Institutional Review Boards (IRB)
approved the studies in which samples were collected, and the
UCSD and UNMC IRBs approved their use in this study. Written
informed consent was received from all participants. To ascertain
whether subjects might have decisional impairment, a Decisional
Capacity Assessment was administered. This consisted of an 11-
item post-consent quiz with questions regarding the nature of the
illness being studied, the voluntary nature of participation, and the
ability to withdraw at any time, the consequences of withdrawing,
the possible risks and benefits of participation, the procedures
involved, the time required, confidentiality, and whom to call with
any questions. Assistance with reading or understanding the
vocabulary was provided. Inability to achieve a perfect score on
the test or other serious indication of questionable capacity
resulted in further evaluation by a clinical psychiatrist, psychol-
ogist, or neurologist. All subjects in this analysis achieved a perfect
score on the test, indicating satisfactory demonstration of capacity.
All participants were ambulatory and underwent evaluation in
the outpatient research center at UCSD. Eligibility criteria
included the ability to undergo a structured clinical interview
and to provide details of combined antiretroviral therapy (cART)
use and substance use history.
Data were collected according to a standardized protocol of
comprehensive neuromedical, neurobehavioral, and laboratory
assessments as described previously [17]. Briefly, the following
clinical parameters were evaluated using structured interviews and
laboratory assessments where appropriate: cART use, including
current and past exposure and HIV disease markers (plasma viral
load and current and nadir CD4+ cell counts). Blood was collected
by venipuncture and used to quantify plasma HIV viral loads by a
commercial reverse transcription polymerase chain reaction assay
(nominal lower quantitation limit, 50 copies/mL [Amplicor;
Roche Diagnostic Systems, Indianapolis, Indiana]). Current
CD4+ cell counts were measured by flow cytometry. Psychiatric
diagnoses, including substance use disorders (abuse and depen-
dence), were assessed using the computer assisted Composite
International Diagnostic Interview (CIDI) [18,19], a fully
structured clinical interview that is widely used in psychiatric
research [20,21]. The CIDI classified current (within in the last 30
days) and lifetime (.30 days ago) histories of METH use (e.g.,
abuse and dependence) disorders.
Materials
Ammonium phosphate, a-cyano-4-hydroxycinammic acid
(CHCA), trifluoroacetic acid (TFA) were from Sigma Aldrich
(St. Louis, MO, USA). HPLC grade water and acetonitrile (ACN)
were from Fisher Scientific (Pittsburg, PA, USA). NuPAGE 4–
12% gels were from Invitrogen Corp. (Carlsbad, CA, USA).
Ready Gel
TM Blotting Sandwiches and glycine were from Bio-Rad
(Hercules, CA, USA). Super SignalH West Pico chemiluminescent
substrate was from Pierce (Rockford, IL, USA). Mouse monoclo-
nal antibodies against vitamin D-binding protein (Abcam, Cam-
bridge, MA, USA), and ceruloplasmin (BD Biosciences, San Jose,
CA, USA) were used as primaries, for detection of secondary
antibodies were polyclonal goat HRP-conjugated anti-mouse IgG
(Jackson ImmunoResearch, West Grove, PA, USA).
Sample processing
Samples had been stored at 280uC from the time of collection
until the time of shipment. Samples were shipped on dry ice from
UCSD to UNMC and, on arrival, remained frozen. HIV was
inactivated in all samples by addition of 10 ml of 10% Triton-X100
freshly made and 50 ml of cocktail of protease inhibitors (Sigma-
Aldrich St. Louis, MO) per 1 mL of sample. After 30 minutes
samples were aliquoted and those unused were stored at 280uC.
Two hundred fifty microliters from each sample were filtered using
0.2 mm spin filter and immunodepleted using an IgY14 column
(Sigma-Aldrich) connected to a liquid chromatography systems
HPLC to immunodeplete abundant plasma proteins: albumin, a1-
antitrypsin, IgM, haptoglobin, fibrinogen, a1-acid glycoprotein,
apolipoprotein A-I and A-III, Apolipoprotein B, IgG, IgA,
transferrin, a2-macroglobulin and complement C3. Flow-through
fractions containing unbound proteins were concentrated using
Vivaspin 15R (Sartorius, Aubagne, France), according to the
manufacturer protocol. Finally, protein concentration was deter-
mined with a NanoDrop spectrophotometer (Thermo Scientific,
San Jose, CA).
Trypsin digest and peptide labeling
Fifty micrograms of proteins were precipitated with ethanol.
Briefly, we added 10 volumes of cold ethanol (200 proof) to each
sample. Samples were incubated for 3 h at 220uC and centrifuged
at 130006g for 15 minutes at 4uC. Proteins pellets were washed
with 1 ml of 70% ethanol and dried in SpeedVac (Thermo-
Scientific). Subsequent solutions were provided with iTRAQ
reagent kit (Applied Biosystem (ABI), Carlsbad, CA).
Dried proteins were solubilized with dissolution solution and
proteins were denatured with 1 ml of denaturant reagent. Proteins
reduction with reducing reagent was performed for 1 h at 60uC
and finally cysteine blocking solution was used to block cysteines
during 10 minutes at room temperature.
Trypsin from ABI was reconstituted at 1 mg/ml with milliQ
water and 10 mg of trypsin were added to each sample. Digestion
was performed for 16 h at 37uC.After digestion, peptides were
labeled with iTRAQ label reagent (ABI) at room temperature for
2 h and 8 samples, labeled with the different isobaric mass tags,
were combined in one tube and dried with SpeedVac.
iTRAQ labeled peptides processing
Having subsequent samples collected from the same individuals
at various times allowed us to make comparisons between time
points as well as across all groups. Because we had four groups and
two time points per group, the 8-plex iTRAQ approach to
quantify changes was the method of choice. Table 1 shows how
samples were ‘‘scrambled’’ into four sets to remove tag labeling
bias. Since Group 1, (HIV+/persistent METH+) had only four
individuals, four samples were randomly chosen from those
available in Groups 2, 3 and 4 (consisting of 8, 12 and 10
identified subjects, respectively). One set of samples utilized all
eight iTRAQ tags and each was measured in a separate analytical
run.
Samples were clarified using mix education exchange (MCX)
column (Water Corp., Milford, MA). Label peptides were
solubilized with 1 ml of 0.1% formic acid, passed through the
column, then the column was first washed with 5% methanol,
0.1% formic acid solution and then with methanol HPLC grade.
Peptides were eluted with 1.4% NH4OH in methanol [22].
Samples were dried, reconstituted in 1.44 ml of 0.1% formic
acid and supplemented with 1.44 ml of OFFGEL solution for
360 ml of peptides. Next, samples were fractionated based on their
isolelectric point (pI) using 3100 OFFGEL Fractionator (Agilent,
Inc. Santa Clara, CA). OFFGEL strips were rehydrated for
15 minutes at room temperature with 40 ml of OFFGEL solution.
HIV and Drug Abuse
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between all 12 wells. Separation was performed for 20,000 Vhrs.
Collected fractions were cleaned with C-18 spin columns,
according to the manufacturer’s protocol. Briefly, fractions were
adjusted to 5% acetonitrile (ACN) and 0.5% trifluoric acid (TFA)
and passed through activated columns. Columns were washed
twice with a 5% ACN, 0.5% TFA solution and peptides were
eluted with a 70% ACN, 0.1% TFA solution. Peptides were finally
dried and stored at 280uC until further use.
Off line LC-MS/MS analysis
Subsequent fractionation of OFFGEL fractions was performed
off-line using Tempo
TM LC system with automatic high density
spotting onto MALDI target plates. Peptides were solubilized in
20 ml of 0.1% TFA and 10 ml of samples were loaded onto a
ProteoCol
TM C18 trap cartridge (MichromBiosources, Auburn,
CA) and washed for 20 minutes at 9 ml/min. Gradient of
separation was realized using a ratio between two buffers,
Water:ACN:TFA (98:2:0.1) (Buffer A) and water:ACN:TFA
(2:98:0.1) (Buffer B). To perform the separation, the subsequent
gradient was applied, time 0 to 5 min 5 to 15% buffer B, 5–
52 minutes 15–35%, 52–54 minutes 35–80%, 54–64 minutes
80%, 64–65 minutes 80—5% and 65–72 minutes 5%. Peptide
elution was monitored with a UV cell at 214 nm absorbance. After
the UV cell, eluted peptides were mixed with a matrix solution
(1.2 mg/ml in 75% ACN and 0.1% TFA solution) at a flow rate
1 ml/minute using a Harvard Apparatus syringe pump. Fractions
were spotted every 30 seconds and voltage applied to the plate
during spotting was 2.8 kV.
Spotted fractions were submitted for data acquisition on a 4800
MALDI-TOF/TOF mass spectrometer (ABI). MS spectra were
acquires from 800 to 3000 m/z, for a total of 1000 laser shots by
an Nd-YAG laser operating at 355 nm and 200 Hz. Laser
intensity remain fixed for all the analyses. MS/MS analyses were
performed using 1 kV collision energy with air as CID gas.
Metastable ions were suppressed, for a total of 1000 laser shots.
Protein identification and quantification were performed with
ProteinPilot
TM software using Paragon method. The search
parameters were as follows: iTRAQ 8plex (peptide labeled),
Methylthio alkylation of Cysteine, NCBI database restricted to
Homo sapiens.
Statistical analysis
Protein/peptide abundance measures generated by iTRAQ
were first pre-processed using ProteinPilot
TM v2.0. The logarithm
of the abundance measure was modeled as a function of animal,
protein, peptide, tag and experimental condition. Four sets of
samples were used to simultaneously collect data from eight
experimental conditions composed of two visits from four groups:
Group 1: HIV+/persistent METH+, Group 2: HIV+/ST METH
abstinent, Group 3: HIV+, LT METH abstinence, Group 4:
HIV-/METH-. All available abundance records (N=77,159)
were normalized using an iterative back fitting procedure to
remove the animal, protein and peptide effects. Comparison of the
distribution of the protein/peptide normalized (log) abundance
measures by experimental condition was restricted to records with
ProteinPilot
TM assessed ‘‘confidence’’ of at least 50%. The mixed
model was fit on the normalized abundances of each protein to
adjust for the correlation of the samples collected from the same
subject. The abundances of each protein between two visits within
the same group were compared, and the relative abundance and
the p-values were calculated to evaluate the short/long term effects
of METH within each group.
Western blot - validation
Western blot quantitation was done as previously described
[22,23]. 1DE was performed using NuPAGE gel system (Invitro-
gen Corp.) in 4–12% gradient Bis-Tris gels under reducing
conditions and transferred onto PVDF membrane. Chemilumi-
nescent signal was detected using SuperSignal West Pico
TMChem-
iluminescent Substrate and recorded on Blue Lite X-ray film
(ISCBioExpress, Kaysville, UT).
Results
Subjects
All subjects visited the research center at least two times during
the study, which allowed us to measure changes in the plasma
proteome between visits. Subject demographic and clinical
characteristics are summarized in Table 2. Group 1 (HIV+/
persistent METH+) has relatively few subjects due to the rarity of
such individuals. METH users entering the study were offered
resources for treatment for their drug abuse if requested (Groups 1,
2 and 3). The study took place in an outpatient setting in which
sobriety/abstinence was not required, thus effects of discontinu-
ation of METH, rather than initiation of METH, were observed.
Blood was drawn during visits and first blood sample was taken at
the first visit. This measure is indirect because it attempts to infer
the effects of METH from its discontinuation rather than from its
administration. On the other hand, it is sufficient given ethical
guidelines because ethically the direct effects of transition from a
normal state to one of METH abuse cannot be clinically studied.
Protein identification and quantitation
Plasma proteomic profiling is made difficult by the presence of a
number of abundant proteins, making examination of less
Table 1. iTRAQ tag assignation for 4 biological replicates in experimental design.
Sample set Tag 113 Tag 114 Tag 115 Tag 116 Tag 117 Tag 118 Tag 119 Tag 121
1 *P1, G2, V1 P2, G4, V2 P2, G4, V1 P3, G1, V2 P1, G2, V2 P4, G3,
V1
P4, G3, V2 P3, G1, V1
2 P5, G2, V2 P6, G3, V1 P7, G1, V1 P6, G3, V2 P8, G4, V1 P7, G1,
V2
P5, G2, V1 P8, G4, V2
3 P9, G3, V2 P10, G1, V1 P11, G2, V2 P9, G3, V1 P11, G2, V1 P12, G4,
V2
P10, G1, V2 P12, G4, V1
4 P13, G4, V2 P14, G2, V1 P15, G1, V2 P13, G4, V1 P16, G3, V1 P14, G2,
V2
P15, G1, V1 P16, G3, V2
*P=Patient; G=Group; V=Visit.
doi:10.1371/journal.pone.0031031.t001
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proteins and the large dynamic range of their concentrations
further complicate analysis. Thus we used multidimensional
separation techniques – immunodepletion of the 14 most
abundant proteins, separation of peptides into bins by isoelectric
points (pI), and then further separation of these pI-based bins by
reverse phase liquid chromatography. We chose the iTRAQ
method of quantitation, and then eliminating label bias by a
scrambling strategy. The data from mass spectrometry analysis
were analyzed separately for each sample set and the results of all
samples sets were then combined, revealing the identification of a
total of 390 proteins. Statistical analysis revealed that 28 proteins
were significantly differentially expressed in the persistent METH
users; these are listed in Table 3.
Effect of persistent METH use and short and long term
abstinence
The primary objective of this study was to gain insights into
changes in plasma proteome induced by METH in HIV-infected
individuals. The study was designed based on participants who
successfully stopped using drugs of abuse, therefore observed
effects measured such change, rather than change induced directly
by drug administration. Changes between visits in all four groups
are summarized in Table 4. Group 1 measures changes in
proteome in HIV-infected individuals when METH was still used,
revealing a large number of changed proteins between visits.
Groups 2 (i.e., reported stopping using METH over the course of
the study for between two to 12 weeks) and Group 3 (i.e., reporting
having at least three months of abstinence) who showed relatively
few changes between visits. Similarly Group 4 (e.g., not HIV-
infected and did not use METH) did not show many changes, thus
in normal individuals the proteome is relatively stable as measured
by our methods. Fig. 1 shows differences between visits for three
selected proteins. Statistical significance (increase) was observed
only in Group 1.
The paucity of changes in the measured proteomes between
visits in Groups 2 and 3 indicated that METH use had limited
effect of these proteins at the time of the first visit, since METH
abstinence in the context of recent use at the first visit (Group 2) or
a history of METH use (Group 3) did not result in changes; as the
amount of change in the proteome did not differ from that found
in controls who were HIV negative and did not use METH
(Group 4). However, many changes were found in Group 1,
consisting of the significant increase of twenty one proteins, and a
decrease of one protein. This effect of METH is very likely due to
a recurring insult from taking METH. This can be either due to
the continued use of METH over this period, and/or recent
METH use; the positive urinary toxicology used to identify
METH use indicates its use within the last three days.
Figure 2 demonstrates that a specific subset of proteins,
designated by the arrows, was differentially perturbed in HIV-
infected persistent METH users (HIV+/persistent METH+). The
majority of these proteins were increased in expression in
association with persistent METH use. A smaller subset of
proteins showed reduced expression. HIV positive individuals
who discontinued METH use (Groups 2 and 3) showed profiles
more similar to those of HIV negative METH negative subjects.
Discussion
Use of METH is associated with multiple adverse health
outcomes such as behavioral risks facilitating sexually transmitted
diseases and mental health problems such as psychosis and
depression [24,25]. A strong association between METH use and
Table 2. Subject demographic, psychiatric, and clinical characteristics.
Variables Group 1 (N=4) Group 2 (N=8) Group 3 (N=12) Group 4 (N=10)
Demographics:
Age, years (mean, SD) 37.8 68.9 38.1 65.6 43.6 69.0 38.4 69.6
Sex, % male (N, %) 3 75% 8 100% 12 100% 7 70%
Education, years (mean, SD) 10 62.3 13 61.9 14 62.0 12.8 62.3
Ethnicity, % Caucasian, N, %) 2 50% 7 88.0% 10 83.0% 5 50.0%
Psychiatric Characteristics:
METH Use Disorder (N, %)
a
Lifetime (.30 days ago) 4 100% 8 100% 12 100% 0 0%
Current (#30 days ago) 2 50% 3 37.5% 0 0% 0 0%
Age of 1st use of METH, years (mean, SD)
b 15.7 64.0 24.3 67.5 31.1 630.0 – –
Days since last use of METH (mean, SD) 5.1 63.0 5.0 62.7 1174.2 63395.0 – –
Total days used METH (mean, SD) 527.0 6912.9 735.7 62080.8 1100.3 62624.7 – –
Total grams of METH used (mean, SD) 5569.5 69646.7 677.3 61915.6 477.5 6889.5 – –
Clinical Characteristics
c:
On CART (N, %) 0 0% 5 63% 6 50% – –
Plasma VL (median, IQR) 4.3 2.4, 5.1 4.4 3.0, 5.2 1.7 1.7, 3.7 – –
Nadir CD4 (median, IQR) 422 119, 953 181 23, 282 168 76, 385 – –
Current CD4 (median, IQR) 579 209, 942 238 76, 427 416 323, 705 – –
Abbreviations: CART=combination antiretroviral therapy; SD=standard deviation; VL=viral load log10 copies/mL; IQR=interquartile range.
aMETH use disorder defined as meeting DSM-IV criteria for METH abuse or dependence.
bThese variables are restricted to METH+ subjects.
cThese variables are restricted to HIV+ subjects.
doi:10.1371/journal.pone.0031031.t002
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[25,26,27]. Despite treatment, HIV infection is associated with a
significant degree of neurocognitive impairment in one out of
every seven subjects [28]. In SIV infected rhesus monkeys, METH
treatment led to immune changes as well as increased virus in the
brain [29]. Therefore, it can be expected that the combined effects
of HIV infection and METH use will have not only additive or
perhaps synergistic adverse effects on the brain, but also will have
a detrimental impact on many physiological functions [30]
including the immune system. We postulated that such effects
would be reflected by changes in plasma proteome. Alterations in
the plasma can affect the brain via communications between the
periphery and the CNS, as well as through breach of blood-brain
barrier (BBB) that can occur in HIV infection as well as drug
abuse.
Interestingly the majority of significant changes were observed
between visits in Group 1, those who did not discontinue using
METH. Two major pathways were affected. First, was the
complement cascade. This system is usually activated by HIV-1
infection alone; here continued METH use leads to further
increase of C4A and C5 components. Such an increase likely
represents non-specific response to an insult [31,32]. The second
activated system was blood coagulation and up-regulation of
plasminogen, fibrinogen and kininogen. It has been shown that
one toxic effect of METH use is disseminated intravascular
coagulation (DIC, consumptive coagulopathy), which is a
pathological activation of coagulation mechanisms [33]. As the
small clots consume coagulation proteins and platelets, normal
coagulation is disrupted; normal blood flow to organs is disrupted
and this can lead to abnormal bleeding [34]. None of the subjects
in this analysis had DIC but reported use of METH, at least in the
setting of concurrent HIV infection, appears to result in less severe
activation of coagulation pathways.
Increased expression of ceruloplasmin and hemopexin can
represent a response to modulate increases in oxidative stress
resulting from HIV infection and METH use. We expected that in
response to METH exposure oxidative stress should be signifi-
cantly enhanced and be correlated to increased expression of
antioxidant enzymes, similar to our findings in SIV infected
monkeys administered a chronic METH regimen [35]. Cerulo-
plasmin is a copper-binding glycoprotein oxidizing Fe
2+ to Fe
3+
ferroxidase without releasing radical oxygen species. Its main
reported function is transport of iron across the cell membrane;
however, several recent reports link this protein to an overall
Table 3. Summary of differentially expressed proteins with statistical significance.
Protein names NCBI accession number
UniProtKB accession
number pI MW (kDa)
Alpha 2 macroglobulin variant gi|167017130 A8K2U0 5.8 161.1
Alpha-1-antichymotrypsin gi|1340142 P01011 5.5 49.8
Alpha-2-glycoprotein 1, zinc-binding gi|52790422 P25311 5.7 34.3
Alpha-2-HS-glycoprotein (Fragment) gi|7770227 P02765 6.4 22.7
Alpha2-HS glycoprotein gi|2521983 P022765 5.4 39.4
Antithrombin III gi|179161 P01008 6.3 52.6
Apolipoprotein B-100 precursor gi|28780 P04114 6.6 515.6
C4A variant protein gi|443671 P0C0L4 6.8 193.7
cDNA FLJ55673, highly similar to Complement factor B gi|194384366 B4E1Z4 6.8 140.9
cDNA FLJ56652, highly similar to Hemopexin gi|221044726 B7Z2Q4 6.4 15.7
Ceruloplasmin precursor gi|119599290 P00450 5.5 116.8
Coagulation factor XI precursor gi|4503627 P03951 8.5 70.1
Complement C5 preproprotein gi|38016947 P01031 6.1 188.3
Fibrinogen gamma chain gi|70906437 P02676 5.7 49.5
Group-specific component (vitamin D-binding protein) gi|34785355 P02774 5.3 52.9
Guanine nucleotide regulatory protein gi|404722 Q14344 8.1 44.1
Hemopexin precursor gi|386789 P02790 6.6 51.4
Immunoglobulin kappa light chain V gi|21669423 No UniProtKB number* 6.7 29.3
Inter-alpha globulin inhibitor H2 gi|70778918 P19823 6.4 106.5
Inter-alpha-trypsin inhibitor family heavy chain-related protein gi|221042206 B7Z544 6.2 98.3
Kininogen-1 isoform 2 gi|156231037 P01042 6.3 72
Leucine-rich alpha-2-glycoprotein 1 gi|21707947 P02750 6.5 38.2
Plasminogenisoform 1 precursor gi|4505881 P00747 7.0 90.6
PREDICTED: similar to immunoglobulin lambda-like polypeptide 1 gi|239752604 No UniProtKB number* 8.9 53.3
Prothrombin; coagulation factor II gi|1335344 P00734 5.5 69.3
Putative uncharacterized protein DKFZp686G11190 gi|34365282 Q6MZQ6 8.3 52.0
Recombinant IgG3 heavy chain gi|9857757 No UniProtKB number* 8.4 89.0
Vitamin D-binding protein/group specific component gi|455970 P02774 5.3 52.9
*The protein sequences have no homolog sequence in UniProtKB database.
doi:10.1371/journal.pone.0031031.t003
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stress. Ceruloplasmin is produced in the liver and our findings
suggest that its expression increases during periods of METH use.
These changes may remit following cessation of METH use,
explaining why we did not observe changes in ceruloplasmin
expression in patients after short or long term METH abstinence.
In our previous plasma and cerebrospinal fluid (CSF) profiling
experiments of HIV-infected individuals we also found cerulo-
plasmin to be differentially expressed [23,36,37]. Interestingly, this
protein was down regulated in CSF of subjects with HIV dementia
whereas it was up-regulated in plasma, suggesting that the CSF-to-
plasma ratio of ceruloplasmin may be an important correlate of
HIV-associated neurocognitive impairment.
The observation that changes in the plasma proteome were
largely limited to subjects who continued to use METH was also
unexpected. Because of this, we could not confidently identify a
signature of METH use versus METH abstinence. Continued use
of METH is by its nature an unstable condition, and users ‘‘crash’’
after METH binges [38]. Similarly the plasma proteome changes
we found in Group 1 were not consistent with adaptive long-term
changes, suggesting that METH use continues to lead to instability
in normal physiology such as the complement and coagulation
systems even during chronic use. It has to be noted that some of
the subjects in Groups 2 and 3 were on treatment for HIV
infection whereas none of those in Group 1 were treated for HIV.
Our previous studies revealed that the proteome changes rapidly
within the first two weeks of infection (acute phase) and comes
back to background, especially if cART is implemented [22]. HIV-
induced changes in proteome become obvious when viral infection
is not well controlled and inflammation is on the rise. Therefore
the relationship between METH use and HIV infection and the
changes found in Group 1 is likely complex.
During the last decade of clinical and translational proteomics
development much emphasis has been placed on technological
development with expectations that more sensitive mass spec-
trometers and multi-level pre-fractionations will lead us to
discovery of multiple new diagnostic biomarkers [39,40]. Howev-
er, the reality showed that although cataloging hundreds or even
thousands of proteins in plasma and CSF has become more and
more routine, quantitation and validation techniques are lagging
Table 4. Changes in plasma protein expression levels between visits in all groups.
1
Names Group 1 p-value Group 2 p-value Group 3 p-value Group 4 p-value
Alpha 2 macroglobulin variant 1.44 ,0.05 21.10 NS 1.35 NS 1.17 NS
Alpha-1-antichymotrypsin 2.09 ,0.001 21.01 NS 1.84 ,0.01 2.01 ,0.01
Alpha-2-glycoprotein 1, zinc-binding 21.12 NS 21.94 ,0.05 1.02 NS 21.82 ,0.05
Alpha-2-HS-glycoprotein (Fragment) 3.86 ,0.001 21.48 NS 1.09 NS 21.01 NS
Alpha2-HS glycoprotein 2.94 ,0.001 21.52 NS 1.14 NS 1.12 NS
Antithrombin III 2.25 ,0.001 1.02 NS 1.43 ,0.05 1.08 NS
Apolipoprotein B-100 precursor 1.20 NS 1.41 NS 1.60 ,0.05 1.36 NS
C4A variant protein 1.44 ,0.005 1.06 NS 21.04 NS 21.27 NS
cDNA FLJ55673, highly similar to Complement factor B 1.33 ,0.05 1.15 NS 1.44 ,0.005 21.32 NS
cDNA FLJ56652, highly similar to Hemopexin 2.21 ,0.001 21.13 NS 1.24 NS 21.15 NS
Ceruloplasmin precursor 1.65 ,0.001 21.19 NS 1.29 NS 21.29 NS
Coagulation factor XI precursor 1.89 ,0.05 21.31 NS 1.42 NS 1.01 NS
Complement C5 preproprotein 2.01 ,0.05 1.30 NS 1.28 NS 1.83 NS
Fibrinogen gamma chain 21.43 NS 21.31 NS 1.57 NS 21.61 NS
Group-specific component (vitamin D-binding protein) 3.05 ,0.001 21.13 NS 1.53 NS 21.03 NS
Guanine nucleotide regulatory protein 22.63 NS 1.27 NS 21.50 NS NS
Hemopexin precursor 1.85 ,0.001 21.13 NS 1.30 NS 21.06 NS
Immunoglobulin kappa light chain V 1.82 ,0.05 21.12 NS 1.06 NS 1.38 NS
Inter-alpha globulin inhibitor H2 1.55 ,0.05 1.11 NS 1.70 ,0.05 1.14 NS
Inter-alpha-trypsin inhibitor family heavy chain-related
protein
1.99 ,0.01 21.03 NS 1.52 NS 21.16 NS
Kininogen-1 isoform 2 1.58 ,0.001 1.02 NS 1.07 NS 1.17 NS
Leucine-rich alpha-2-glycoprotein 1 1.58 ,0.05 21.11 NS 1.82 ,0.05 21.03 NS
Plasminogenisoform 1 precursor 1.74 ,0.005 1.00 NS 1.12 NS 21.19 NS
PREDICTED: similar to immunoglobulin lambda-like
polypeptide 1
2.57 ,0.01 21.39 NS 1.21 NS 1.18 NS
Prothrombin; coagulation factor II 1.96 ,0.001 1.08 NS 1.20 NS 1.06 NS
Putative uncharacterized protein DKFZp686G11190 2.65 ,0.005 21.33 NS 1.32 NS 1.26 NS
Recombinant IgG3 heavy chain 2.59 ,0.05 21.28 NS 1.36 NS 1.21 NS
Vitamin D-binding protein/group specific component 2.37 ,0.001 21.09 NS 1.37 NS 21.07 NS
NS: p-value is not significant.
1- Changes are relative increases or decreases from the second visit compared to the first expressed as averaged for each group.
doi:10.1371/journal.pone.0031031.t004
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three proteins showed significant increase from visit one to visit two in Group 1. No changes in other groups of subjects were found.
doi:10.1371/journal.pone.0031031.g001
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h o wt oc o n n e c td i f f e r e n t i a l l ye x pressed proteins to biology of
disease and to judge whether a potential biomarker is specific
and directly relevant to the pathology in question [42,43].
Another layer of complexity is correlating genomic and
proteomic data into one, synthesizing within a comprehensive
and biologically meaningful scheme [44,45]. Much progress has
been made in this area during the last decade when genomic
and proteomic data from cellular proteins are compared. In the
case of secreted proteins, especially those expressed by multiple
tissues, such connections are even harder to make [45,46]. Also
our knowledge about molecular mechanisms governing CNS
and periphery communication is lagging and will require further
investigations of BBB function to better interpret changes in
proteomes of these two compartments. Considering studies
performed so far [ref], there is no clear answer whether we
should or should not expect such correlations and what they are
indicative of biologically.
Conclusions
Our study is the first report of systematic proteomic profiling of
plasma samples, aiming to address the question of the effect of
METH use or abstinence using well-defined groups of research
subjects. Based on our results, we draw three conclusions for the
effect METH use on the plasma proteome in the people living with
HIV disease. First, changes in the hosts’ responses to METH use
may be short lived or require continued METH use to reach
detectable levels. Second, the effect of METH is reflected by
changes in plasma proteins that are linked to oxidative stress and
inflammation. Third, METH use perturbs blood coagulation
pathways, with upregulation of plasminogen, fibrinogen and
kininogen. Consumption of clotting factors in a coagulation
cascade may result in an imbalance between pro- and anti-
coagulation. This could in turn increase the risk of both ischemic
and hemorrhagic end-organ disease. Recent epidemiological
studies demonstrated substantial increases in intracerebral hem-
orrhage and myocardial infarction in young adults abusing
METH [47], thus our work may provide insight into such
complications of METH use, whether in the setting of HIV
infection or in its absence.
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